Kaleido Biosciences, Inc (KLDO)

Etorro trading 970x250
Kaleido Biosciences, Inc (KLDO) Logo

About Kaleido Biosciences, Inc

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Address: 65 Hayden Avenue, Lexington, MA, United States, 02421

Kaleido Biosciences, Inc News and around…

Latest news about Kaleido Biosciences, Inc (KLDO) common stock and company :

Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
18 Apr, 2022 Yahoo! Finance

Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
17 Apr, 2022 FinancialContent

Biotech stocks retreated in the week endingApril 14, lock-stepping with the broader market. The news flow was light during the ...

12 Health Care Stocks Moving In Thursday's After-Market Session
14 Apr, 2022 FinancialContent

Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 10.3% to $0.32 during Thursday's after-market session. Today's trading ...

12 Health Care Stocks Moving In Thursday's Intraday Session
14 Apr, 2022 FinancialContent

Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 24.9% to $0.38 during Thursday's regular session. As of 13:30 EST, ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
14 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Apr, 2022 FinancialContent

Gainers Kaleido Biosciences (NASDAQ:KLDO) shares moved upwards by 105.3% to $0.35 during Wednesday's regular session. Kaleido ...

Why Is Creatd (CRTD) Stock Up Today?
13 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Creatd (CRTD) stock is heading higher on Wednesday following news of a deal for wellness beverage subsidiary Dune Glow Remedy. The post Why Is Creatd (CRTD) Stock Up Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Dear KLDO Stock Fans, Mark Your Calendars for April 28
13 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kaleido Biosciences (KLDO) stock is soaring on Wednesday but anyone considering a stake in the company will want to keep an eye on April 28. The post Dear KLDO Stock Fans, Mark Your Calendars for April 28 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
13 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Apr, 2022 FinancialContent

Gainers Alzamend Neuro (NASDAQ:ALZN) shares rose 19.6% to $1.22 during Tuesday's after-market session. Today's trading volume for ...

Monday Sector Laggards: Shipping, Biotechnology Stocks
11 Apr, 2022 FinancialContent

In trading on Monday, shipping shares were relative laggards, down on the day by about 4.2%. Helping drag down the group were shares of Singularity Future Technology, down about 31.9% and shares of Eagle Bulk Shipping off about 8.9% on the day.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
11 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, investor! It's time to start off another week of trading with the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Friday's Intraday Session
08 Apr, 2022 FinancialContent

Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 ...

Stocks That Hit 52-Week Lows On Friday
08 Apr, 2022 FinancialContent

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week ...

Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
08 Apr, 2022 FinancialContent

Kaleido Biosciences Inc(NASDAQ: KLDO) has delivered formal notice to voluntarily delistits common stock from NASDAQ as ...

Friday Sector Laggards: Biotechnology, Semiconductors
08 Apr, 2022 FinancialContent

In trading on Friday, biotechnology shares were relative laggards, down on the day by about 2%. Helping drag down the group were shares of Kaleido Biosciences, down about 76.5% and shares of BioCryst Pharmaceuticals off about 31.5% on the day.

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022
04 Apr, 2022 FinancialContent

Upgrades According to Scotiabank, the prior rating for Welltower Inc (NYSE:WELL) was changed from Sector Perform to Sector Outperform. ...

Novartis (NVS) Beovu Gets Label Expansion for DME in EU
01 Apr, 2022 Yahoo! Finance

Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
31 Mar, 2022 Yahoo! Finance

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal
30 Mar, 2022 Yahoo! Finance

Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.

Bristol Myers (BMY) Application for Opdivo With Chemo Validated
29 Mar, 2022 Yahoo! Finance

Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.

Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah
28 Mar, 2022 Yahoo! Finance

Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.

Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months
28 Mar, 2022 Yahoo! Finance

Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.

Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?
25 Mar, 2022 Yahoo! Finance

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Rezolute (RZLT) Posts Positive Data From Congenital HI Study
24 Mar, 2022 Yahoo! Finance

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

ORIC Stock Plunges on Discontinuation of Oncology Candidate
23 Mar, 2022 Yahoo! Finance

ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.

Bristol Myers' (BMY) Opdualag Wins FDA Nod for Melanoma
21 Mar, 2022 Yahoo! Finance

Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.

Radius Health Announces Leadership Appointments
16 Mar, 2022 Yahoo! Finance

BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company’s Chief Financial Officer. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Mark Conley is a Certified Public Accountant with over 30 years of experience in pub

Adicet Bio, Inc. (ACET) Reports Q4 Loss, Tops Revenue Estimates
15 Mar, 2022 Yahoo! Finance

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -6.82% and 17.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
15 Mar, 2022 Yahoo! Finance

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

Kaleido Biosciences, Inc (KLDO) is a NASDAQ Common Stock listed in , ,

970x250